Therefore, considering that it is impossible to cure all NAFLD patients with a single target, we speculate that the combination of a USP25 agonist and a PPARα agonist may be a promising strategy for NAFLD therapy. This evidence concerns the gene USP25 and metabolic dysfunction-associated steatotic liver disease.